Alfuzosin Hydrochloride
Product Images NDC 0440-5000

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 0440-5000). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Liberty Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dia1 (Alfuzosin Tablet 1)

Chemical structure of Alfuzosin hydrochloride showing its molecular components and bonding arrangement, as presented in the diagram.*

FDA Label Image

Alf4 (Alfuzosin Tablet 2)

A line graph showing Alfuzosin plasma concentration (ng/mL) over time (hours) comparing fed and fasted states. The fed state line exhibits higher plasma concentrations with a peak around 8 hours, while the fasted state shows lower concentrations with a flatter curve. Error bars indicate variability at each time point.*

FDA Label Image

Dia6 (Alfuzosin Tablet 3)

A line graph showing mean change over days of treatment comparing Alfuzosin HCl to placebo. The x-axis represents days of treatment (0, 28, 56, 84), and the y-axis represents mean change. The graph presents data points for two groups: Alfuzosin HCl (N=170) and placebo (N=167), with Alfuzosin HCl showing a greater decrease over time. Statistical significance (p < 0.001) is noted.*

FDA Label Image

Dia7 (Alfuzosin Tablet 4)

A line graph comparing median change over days of treatment for Alfuzosin hydrochloride versus placebo. The x-axis shows days of treatment (0, 28, 56, 84), and the y-axis shows median change. Alfuzosin hydrochloride demonstrates a larger median change over time compared to placebo. Statistical significance is indicated (p < 0.01).*

FDA Label Image

Dia8 (Alfuzosin Tablet 5)

A line graph depicting mean change over days of treatment for two groups: Placebo (N=150) and Alfuzosin HCl (N=151). The X-axis shows days of treatment (0, 28, 56, 84) and the Y-axis shows mean change in values, with Alfuzosin HCl showing a greater decrease over time compared to placebo. Statistical significance is indicated by ** p < 0.01.*

FDA Label Image

Dia9 (Alfuzosin Tablet 6)

A line graph depicting the mean change in mL/s over days of treatment (0, 28, 56, 84) comparing Alfuzosin hydrochloride (Alfuzosin HCl) with placebo. Alfuzosin shows a steady increase in mean change, while placebo remains near baseline. Statistical significance is indicated with p < 0.001.*

FDA Label Image

Dia10 (Alfuzosin Tablet 7)

Line graph comparing mean change in a variable over 84 days of treatment between a placebo group (N=147) and an Alfuzosin HCl group (N=138). The y-axis represents mean change in ml/s, and the x-axis shows days of treatment at 0, 14, 28, 56, and 84 days. Alfuzosin HCl shows a greater increase relative to placebo over time, with a significant difference at day 84 (p<0.05).*

FDA Label Image

Dia11 (Alfuzosin Tablet 8)

A line graph comparing mean change in mL/s over days of treatment (0 to 84) between Placebo (N=150) and Alfuzosin HCl (N=151). Alfuzosin shows a higher increase than placebo, peaking around day 28 before slightly declining, with a note indicating NS p > 0.05.*

FDA Label Image

Image (Alfuzosin Tablet 9)

Label for Alfuzosin ER 10 mg extended-release tablets, generic for Uroxatral, packaged by Aidarex Pharmaceuticals LLC and produced for U.S. Government Medical Facilities. The label shows 90 tablets per bottle and includes manufacturer information for Invagen Pharmaceuticals, Inc. The label has dosage, lot, and expiration date fields, with usage instructions and a federal law caution statement.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.